Shenzhen TargetRx
Shenzhen, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $50M
Overview
A precision oncology company developing small-molecule drugs for difficult-to-treat cancers.
Oncology
Technology Platform
A platform combining structural biology and computational chemistry for the rational design of small molecules against challenging oncology targets.
Funding History
1Total raised:$50M
Series C$50M
Opportunities
Successfully drugging a validated but elusive target could lead to a breakthrough therapy with significant commercial and clinical impact.
Risk Factors
High technical risk associated with pioneering novel chemical matter for difficult targets, with a potential for preclinical failure.
Competitive Landscape
Operates in the highly competitive 'drugging the undruggable' space, competing with both large pharma divisions and well-funded biotechs like Revolution Medicines and Relay Therapeutics.